Liquidia Shares Fall 10% After United Therapeutics' New Drug Announcement
Liquidia (LQDA) shares fell 10% following United Therapeutics' (UTHR) surprise unveiling of TreSMI, a next-gen inhaled treprostinil aimed at reducing cough, despite no disclosed clinical data and plans to file later this year, Needham tells investors in a research note. The reaction appears overdone, as Yutrepia's preliminary Q4 sales are already known and the key near-term catalyst remains the pending '327 patent litigation decision, the firm says.
